Mallinckrodt plc to Report Fourth Quarter and Fiscal Year 2024 Financial Results

Rhea-AI Summary

Mallinckrodt has scheduled the release of its fourth quarter and fiscal year 2024 financial results for Tuesday, March 11, 2025. The global specialty pharmaceutical company will host an investor conference call at 8:00 a.m. ET on the same day. Participants can access the call through registration links provided, with options including an audio-only webcast and replay availability through the company's Investor Relations webpage.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

DUBLIN, Feb. 27, 2025 /PRNewswire/ -- Mallinckrodt plc, a global specialty pharmaceutical company, today announced that it will report its fourth quarter and fiscal year 2024 financial results on Tuesday, March 11, 2025. 

A conference call for investors will begin at 8:00 a.m. ET and can be accessed as follows:

• Live Call Participant Registration (including dial-in): https://register.vevent.com/register/BIf17087938ddc47079bf48d6d5e7c5687
• Audio Only Webcast Link (live and replay): https://edge.media-server.com/mmc/p/igfp4swa
• On the Investor Relations page of the Mallinckrodt website: https://ir.mallinckrodt.com/

ABOUT MALLINCKRODT
Mallinckrodt is a global business consisting of multiple wholly owned subsidiaries that develop, manufacture, market and distribute specialty pharmaceutical products and therapies. The Company's Specialty Brands reportable segment's areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, nephrology, pulmonology, and ophthalmology; neonatal respiratory critical care therapies; and gastrointestinal products. Its Specialty Generics reportable segment includes specialty generic drugs and active pharmaceutical ingredients. To learn more about Mallinckrodt, visit www.mallinckrodt.com. 

Mallinckrodt uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. It also uses its website to expedite public access to time-critical information regarding the Company in advance of or in lieu of distributing a press release or a filing with the U.S. Securities and Exchange Commission ("SEC") disclosing the same information. Therefore, investors should look to the Investor Relations page of the website for important and time-critical information. Visitors to the website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations page of the website.

Investor Relations Contact
Derek Belz
Vice President, Investor Relations
314-654-3950
derek.belz@mnk.com

Mallinckrodt, the "M" brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company. © 2025.

View original content to download multimedia:https://www.prnewswire.com/news-releases/mallinckrodt-plc-to-report-fourth-quarter-and-fiscal-year-2024-financial-results-302387746.html

SOURCE Mallinckrodt plc

FAQ

When will Mallinckrodt (MNK) release Q4 and FY 2024 earnings?

Mallinckrodt will release Q4 and FY 2024 earnings on Tuesday, March 11, 2025.

What time is Mallinckrodt's (MNK) Q4 2024 earnings call?

The earnings conference call is scheduled for 8:00 a.m. ET on March 11, 2025.

How can investors access Mallinckrodt's (MNK) Q4 2024 earnings call?

Investors can access the call via registration link, audio webcast, or through Mallinckrodt's Investor Relations website.

Will there be a replay available for Mallinckrodt's (MNK) Q4 2024 earnings call?

Yes, a replay will be available through the audio webcast link and the company's Investor Relations website.